Wang Fengyun, Zhou Lixin, Eliaz Amity, Hu Chang, Qiang Xinhua, Ke Li, Chertow Glenn, Eliaz Isaac, Peng Zhiyong
Department of Critical Care Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China.
Department of Critical Care Medicine, The First People's Hospital of Foshan, Foshan, China.
Front Physiol. 2023 Feb 23;14:1090724. doi: 10.3389/fphys.2023.1090724. eCollection 2023.
Acute kidney injury (AKI) is a common condition with high morbidity and mortality, and is associated with the development and progression of chronic kidney disease (CKD). The beta-galactoside binding protein galectin-3 (Gal3), with its proinflammatory and profibrotic properties, has been implicated in the development of both AKI and CKD. Serum Gal3 levels are elevated in patients with AKI and CKD, and elevated Gal3 is associated with progression of CKD. In addition, Gal3 is associated with the incidence of AKI among critically ill patients, and blocking Gal3 in murine models of sepsis and ischemia-reperfusion injury results in significantly lower AKI incidence and mortality. Here we review the role of Gal3 in the pathophysiology of AKI and CKD, as well as the therapeutic potential of targeting Gal3.
急性肾损伤（AKI）是一种常见疾病，发病率和死亡率都很高，并且与慢性肾脏病（CKD）的发生和进展相关。β-半乳糖苷结合蛋白半乳凝素-3（Gal3）具有促炎和促纤维化特性，已被证实与AKI和CKD的发生有关。AKI和CKD患者的血清Gal3水平升高，而Gal3升高与CKD的进展相关。此外，Gal3与危重症患者AKI的发生率有关，在脓毒症和缺血再灌注损伤的小鼠模型中阻断Gal3可显著降低AKI的发生率和死亡率。在此，我们综述Gal3在AKI和CKD病理生理学中的作用，以及靶向Gal3的治疗潜力。
